News und Analysen

Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued advice on the use of PAXLOVID™ (nirmatrelvir

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, has executed a multi-year

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ^® / XELJANZ^® XR (tofacitinib) for the

Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, launched a series of efforts to assist its members, employees and communities in the Midwest and southern part

Agilent Technologies Inc. (NYSE: A) today announced the company will deliver presentations at the Goldman Sachs 14^th Annual Healthcare CEOs Unscripted Conference and the J.P. Morgan 40^th Annual

Pfizer Inc. (NYSE: PFE) today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients)

Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.40 for the first-quarter 2022 dividend

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved the 100 mg and 200 mg doses of Cibinqo^® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the

Humana Military, a wholly owned subsidiary of Humana Inc. (NYSE: HUM), announced today that it has earned a three-year Case Management Accreditation and a Disease Management Accreditation from URAC

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine

Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live webcast of a presentation and conference call with investment analysts at 8:30 a.m. EST on Friday, December 17

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from

Loudoun Medical Group, P.C. (LMG), one of the largest and most diverse physician-owned, multi-specialty group practices in Virginia, and leading health and well-being company Humana Inc. (NYSE